Skip to main content
Fig. 4 | BMC Neurology

Fig. 4

From: Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis

Fig. 4

Forest plot of CGRP mAb vs. placebo for the reduction of 50% responder rates. The estimated pooled RR was 1.51 (95% CI, 1.37 to 1.66) with high statistical significance (P < 0.00001). There was moderate heterogeneity among the studies (I2 = 48%). CI confidence interval, RR risk ratio

Back to article page